
Board of Directors

- Leonard J. Alter, Chairman; Emeritus, Elan CEO and Founder
- Robert D. Bartlett, M.D., Ph.D., Chairman of Scientific Advisory Board
- Susan G. Buffett, Founder and Chair, The Buffett Foundation
- Jed Black, Ph.D., President and CEO, Elan
- John C. C. Chen, Ph.D., President and CEO, Elan
- Robert F. Koepsel, M.D., Chief Medical Officer, Elan
- Robert H. Lefrak, Chairman, The Lefrak Organization
- Robert Lefrak, President, The Lefrak Organization
- Robert McDonald, President and CEO, Boehringer Ingelheim

Advisory Council

- Carol E. Bertozzi, Ph.D., Stanford University
- John P. Bergstrom, Ph.D., Chief Science Officer, Elan
- Andrew S. Davidoff, M.D., Managing Director, Alexion
- David S. Finn, M.D., President, AmerisourceBergen
- Amy Tsai, President, Financial Services

Business Development Committee

- Nancy G. Chiang, Chief Operating Officer
- Howard Fink, M.D., Executive Director
- Terrence Robinson, Director of Scientific Affairs
- Filomena M. Mancuso, Director of Scientific Affairs
- Amrit Singh, Chief Commercial Officer, Elan
- Kate Furler, Chief Financial Officer
- Lisa S. Furler, Senior Managing Director
- Leslie J. Seigler, Director, Public Relations
- John J. Weis, Jr., President, Elan

Staff

- Howard Fink, M.D., Chief Operating Officer
- Suzanne Graubard, Director of Scientific Affairs
- Relinda Jordan, Director, Financial Services
- Brian Murdock, Director of Development
- David H. Silver, Director of Development
- Friedemann Weber, Scientific Director
- Kathy Wadhwa, Director of Development

The funding of Neurofibromatosis 1 (NF1) programs was initiated by the NIH. However, this effort is expected to improve outcome for patients with NF1 and related disorders. NF1 is the most frequent genetic disorder, affecting an estimated 1 in 3,000 people. It is a complex disorder with a wide spectrum of symptoms and can affect any part of the body. The aim of the effort is to develop targeted therapies for NF1, which will improve the quality of life for patients and reduce the burden of the disease.
Hope is on the horizon and it is being expeditied by marrying smart business strategies with philanthropic giving.

**INNOVATIVE VISION: THE CONTINUITY ANTHOLOGY CONTINUES TO BE THE DRIVING FORCE BEHIND ADOF'S MISSION. IT DIFFERENTIATES THIS CHINA FROM OTHERS IN PURSUIT OF A CURE FOR AD. ARRIVING BEST PRACTICES IN VIRTUAL CAPITAL INVESTING TO A NON-PROFIT GAIN AWARDS X-FACTOR AND MAKE A POSTIVE IMPACT ON THE FIELD.**

When ADOF's six-year, non-stop educational program's related investment assets in 1999 were only a handful of drugs in clinical trials, Momentum of 06 was already being conducted, several of which received pre-clinical funding from ADOF. During 2006, ADOF and NASA formed the largest preventive and therapeutic programs at leading academic institutions and biotechnology companies worldwide. Along with work by research scientists in academia and industry, the drug development pipeline has continued to expand and accelerate for producing disease modifying treatments.

In an effort to expand the field, the ADOF made the ADOS in 2006. Maximizing a successful record in biotechnology investment, the ADOF developed a significant philanthropic fund for Alzheimer's Drug Discovery Program (ADSP). For a period of three years, the fund was supported in excess of $24 million, and was a key part of the ADOF's $75 million required to be raised by April 1, 2007. By year's end, the ADOF raised $18,000,000 and secured $12,000,000 in funding. With such an enviable record, we anticipate that the fund will grow to be even larger.

This project, along with other ongoing partnerships, has stimulated individuals, foundations, and organizations to align with the ADOF and work in concert to cure AD. Hope is on the horizon and it is being expedited by marrying smart business strategies with philanthropic giving. Jour the ADOF and become a partner philanthropist responsible for changing the health of humankind.